C9orf72 and frontotemporal dementia: TPN‐101 (censavudine), a reverse‐transcriptase inhibitor originally developed for the treatment of HIV infection, is currently in Phase 2 clinical trials to test its safety and efficacy in PSP and ALS or FTD associated with C9orf72 gene repeat expansion.